INTRODUCTION Point prevalence surveys are widely described as a useful tool for evaluating antimicrobial policy and adherence to guidelines. OBJECTIVES We aimed to investigate if data from the European Centre for Disease Prevention and Control (ECDC) point prevalence survey of healthcare‑associated infections and antimicrobial use (PPS HAI&AU) canbe used to evaluate adherence to national guidelines for the treatment of community‑acquired pneumonia (CAP) and to analyze the quality of treatment regimens. PATIENTS AND METHODS Data for 72 698 patients were collected in Poland between the years 2012 and 2015 according to the ECDC Protocol v.4.2. CAP was an indication for antimicrobial treatment in 3608patients. Patients hospitalized longer than 48 hours were excluded. A total of 667 patients met the inclusion criteria, and 79 regimens were recorded and evaluated as concordant or discordant with the guidelines. Afterwards, 7 experts scored the regimens from 1 to 5. The averages were calculated, and the results below 3.0 were considered as not optimal and those of 3.0 or higher-as optimal. Coherence of the experts' scores was evaluated. RESULTS Of all patients, 153 (22.8%) were treated exactly according to the guidelines. Nineteen regimens (24.0%) were optimal but discordant with the guidelines; they were administered to 346 patients (51.9%). The remaining 50 regimens (63.3%) were evaluated as discordant and not optimal and were used in 169 patients(25.3%). The correlation results of the experts' scores were significant. CONCLUSIONS ECDC PPS HAI&AU data can be efficiently used to assess adherence to guidelines. Despite low adherence (22.8%), almost 75% of patients received optimal antimicrobial treatments. Actions promoting the guidelines and time‑series studies analyzing improvement of adherence should be considered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.20452/pamw.4209 | DOI Listing |
Sci Rep
December 2024
Department of Public Health Sciences and Paediatrics, University of Turin, Turin, Italy.
Healthcare-associated infections (HAIs) represent a major threat in Europe. Infection prevention and control (IPC) measures are crucial to lower their occurrence, as well as antimicrobial stewardship to ensure appropriate use of antibiotics. Starting from Italian national data, this study aimed at: (i) describing IPC indicators, prevalence of HAIs, antimicrobial use and appropriateness of antibiotic use in Italy; (ii) estimating effects of IPC variables on HAI prevalence and on the proportion of antibiotics without specific reason.
View Article and Find Full Text PDFAntibiotics (Basel)
October 2024
Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
Antimicrobial resistance (AMR) is a global problem that results in high morbidity and mortality, particularly in low- and middle-income countries. Inappropriate use of antimicrobials is a major driver of AMR. This study aimed to evaluate the rate and quality of antimicrobial prescription and use at the University Teaching Hospital of Kigali (CHUK), a tertiary-referral teaching hospital.
View Article and Find Full Text PDFJ Trop Pediatr
October 2024
Department of Paediatrics and Child Health, Inkosi Albert Luthuli Hospital and University of KwaZulu-Natal, Durban, 4091, South Africa.
Antimicrobial resistance is a global threat in children, and the emergence of multi-drug-resistant organisms is of concern. This secondary analysis of an antimicrobial point prevalence survey (PPS) in children evaluates the impact of age on antimicrobial use. The mean antimicrobial prescriptions were assessed in neonates, infants, young children (1-5 years), school-going children (6-12 years), and adolescents (13-15 years) from a cross-sectional PPS at three academic hospitals between September 2021 and January 2022.
View Article and Find Full Text PDFInfect Control Hosp Epidemiol
October 2024
Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Diabetes Ther
November 2024
Department of Endocrinology, Civil Aviation General Hospital, Beijing, China.
Introduction: We aim to evaluate the efficacy and safety of pioglitazone/metformin fixed-dose combination (FDC) versus uptitrated metformin in patients with type 2 diabetes mellitus (T2DM) without adequate glycemic control.
Methods: A total of 304 patients were recruited from 15 hospitals in China and randomly assigned (1:1) to the test group (pioglitazone/metformin FDC, 15/500 mg) or the control group (uptitrated metformin, 2000-2500 mg/day). The primary endpoint was the proportion of patients with glycated hemoglobin A1c (HbA1c) ≤ 6.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!